Brightfield Multiplex Immunohistochemistry Assay for PD-L1 Evaluation in Challenging Melanoma Samples.
Journal
Applied immunohistochemistry & molecular morphology : AIMM
ISSN: 1533-4058
Titre abrégé: Appl Immunohistochem Mol Morphol
Pays: United States
ID NLM: 100888796
Informations de publication
Date de publication:
21 Aug 2024
21 Aug 2024
Historique:
received:
22
05
2024
accepted:
16
07
2024
medline:
21
8
2024
pubmed:
21
8
2024
entrez:
21
8
2024
Statut:
aheadofprint
Résumé
Targeting the PD1/PD-L1 immune checkpoint pathway has rapidly become a therapeutic strategy for melanoma patients. Indeed, the quantification of PD-L1 expression by immunohistochemistry (IHC) in melanoma samples is already required, in some contexts, to allow access to anti-PD-1/PD-L1 immunotherapy. Despite a rising demand for PD-L1 testing, paralleling increasing cumulative experience in its assessment and quantification, it is fair to recognize that PD-L1 evaluation in melanoma samples still presents some critical issues. The aim of this technical report is to develop and validate a multiplex double staining protocol for PD-L1/SOX10 in Ventana Benchmark Ultra for routine practice. Our results show that double labeling provides the necessary tools to identify PD-L1+ melanoma cells clearly. The simultaneous visualization of 2 different proteins targets allows the topographical relationship between the 2 labeling to be evaluated within the context of the tissue morphology. Future studies are needed to test this technique's real-world applicability and effectiveness in implementing interpathologist agreement.
Identifiants
pubmed: 39166464
doi: 10.1097/PAI.0000000000001219
pii: 00129039-990000000-00189
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Arnold M, Singh D, Laversanne M, et al. Global burden of cutaneous melanoma in 2020 and Projections to 2040. JAMA Dermatol. 2022;158:495–503.
Lai-Kwon J, Inderjeeth AJ, Lisy K, et al. Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review. Eur J Cancer. 2023;184:83–105.
Chen PL, Roh W, Reuben A, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 2016;6:827–837.
Mandalà M, Merelli B, Massi D. PD-L1 in melanoma: facts and myths. Melanoma Manag. 2016;3:187–194.
Madore J, Vilain RE, Menzies AM, et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res. 2015;28:245–253.
Vranic S, Gatalica Z. PD-L1 testing by immunohistochemistry in immuno-oncology. Biomol Biomed. 2023;23:15–25.
Jiang X, Zhou J, Giobbie-Hurder A, et al. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res. 2013;19:598–609.
Massi D, Brusa D, Merelli B, et al. PD-L1 marks a subset of melanomas with a shorter survival and distinct genetic and morphological characteristics. Ann Oncol. 2014;25:2433–2442.
Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4:127ra37.
Girault I, Adam J, Shen S, et al. APD-1/PD-L1 proximity assay as a theranostic marker for PD-1 blockade in patients with metastatic melanoma. Clin Cancer Res. 2022;28:518–525.
Huang RSP, Tse JY, Harries L, et al. Variable genomic landscapes of advanced melanomas with heavy pigmentation. Oncologist. 2022;27:655–662.
O’Malley DP, Yang Y, Boisot S, et al. Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases. Mod Pathol. 2019;32:929–942.
Schats KA, Van Vré EA, De Schepper S, et al. Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system. Histopathology. 2017;70:253–263.
Schats KA, Van Vré EA, Boeckx C, et al. Optimal evaluation of programmed death ligand-1 on tumor cells versus immune cells requires different detection methods. Arch Pathol Lab Med. 2018;142:982–991.
Krigsfeld GS, Prince EA, Pratt J, et al. Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types. J Clin Pathol. 2020;73:656–664.
Darmon-Novello M, Adam J, Lamant L, et al. Harmonization of PD-L1 immunohistochemistry and mRNA expression scoring in metastatic melanoma: a multicenter analysis. Histopathology. 2022;80:1091–1101.
Paver EC, Cooper WA, Colebatch AJ, et al. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Pathology. 2021;53:141–156.
Massi D, Brusa D, Merelli B, et al. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600. Ann Oncol. 2015;26:1980–1987.
Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1therapy. Clin Cancer Res. 2014;20:5064–5074.
Ugolini F, Pasqualini E, Simi S, et al. Brightfield multiplex immunohistochemistry assay for tumor microenvironment evaluation in melanoma tissues. Cancers (Basel). 2022;14:3682.
Mercier A, Conan-Charlet V, Quintin-Roué I, et al. Reproducibility in PD-L1 immunohistochemistry quantification through the tumor proportion score and the combined positive score: could dual immunostaining help pathologists? Cancers (Basel). 2023;15:2768.
Daud AI, Wolchok JD, Robert C, et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol Am Soc Clin Oncol. 2016;34:4102–4109.
Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol. 2022;40:127–137.
Rimm DL, Han G, Taube JM, et al. A Prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. JAMA Oncol. 2017;3:1051–1058.
Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 Immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2017;12:208–222.
Long GV, Swetter SM, Menzies AM, et al. Cutaneous melanoma. Lancet. 2023;402:485–502.